The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
SUMMARY RAS genes are commonly mutated in cancer; however, RAS mutations are rare in breast cancer, despite the fact that Ras and ERK are frequently hyperactivated. Here we report that the RasGAP gene, RASAL2, functions as a tumor and metastasis suppressor. RASAL2 is mutated or suppressed in human breast cancer and RASAL2 ablation promotes tumor growth, progression, and metastasis in mouse models. In human breast cancer RASAL2-loss is associated with metastatic disease, low RASAL2 levels correlate with recurrence of luminal B tumors, and RASAL2 ablation promotes metastasis of luminal mouse tumors. Additional data reveal a broader role for RASAL2 inactivation in other tumor-types. These studies highlight the expanding role of RasGAPs and reveal an alternative mechanism of activating Ras in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“NF1 also is lost or suppressed in sporadic cancers, including glioblastoma (Cancer Genome Atlas Research Network, 2008; Parsons et al., 2008; McGillicuddy et al., 2009), nonsmall cell lung cancer (Ding et al., 2008), neuroblastoma (Hölzel et al., 2010), and melanoma (Krauthammer et al., 2012;…”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 1×
“Gene expression data and relapse-free and overall survival information were analyzed as previously described (Györffy et al., 2010).”
MethodSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 2×
“, 2009), nonsmall cell lung cancer (Ding et al., 2008), neuroblastoma (Hölzel et al.”
BackgroundBreast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Self-citationThe clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 3×
“RASAL2 in Primary Human Breast Cancers Genomic analyses demonstrate that RASAL2 mutations do occur in human breast cancer but are relatively rare (Bamford et al., 2004; Sjöblom et al., 2006; Shah et al., 2012; Table S1).”
BackgroundThe functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Research works printed but not linked: 29
- Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br. J. Cancer, 91, 355, 10.1038/sj.bjc.6601894 · DOI · Paper page
- Bernards, 2003, GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila, Biochim. Biophys. Acta, 1603, 47
- 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
- Cawthon, 1990, A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations, Cell, 62, 193, 10.1016/0092-8674(90)90253-B · DOI · Paper page
- Dote, 2004, Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer, Clin. Cancer Res., 10, 2082, 10.1158/1078-0432.CCR-03-0236 · DOI
- Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
- Gewinner, 2009, Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling, Cancer Cell, 16, 115, 10.1016/j.ccr.2009.06.006 · DOI · Paper page
- Guy, 1992, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc. Natl. Acad. Sci. USA, 89, 10578, 10.1073/pnas.89.22.10578 · DOI · Paper page
- Herschkowitz, 2007, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol., 8, R76, 10.1186/gb-2007-8-5-r76 · DOI · Paper page
- Hollestelle, 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines, Mol. Cancer Res., 5, 195, 10.1158/1541-7786.MCR-06-0263 · DOI · Paper page
- Hölzel, 2010, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome, Cell, 142, 218, 10.1016/j.cell.2010.06.004 · DOI · Paper page
- Hu, 2006, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, 7, 96, 10.1186/1471-2164-7-96 · DOI · Paper page
- Hu, 2008, Regulation of in situ to invasive breast carcinoma transition, Cancer Cell, 13, 394, 10.1016/j.ccr.2008.03.007 · DOI · Paper page
- Jézéquel, 2012, bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer, Breast Cancer Res. Treat., 131, 765, 10.1007/s10549-011-1457-7 · DOI · Paper page
- Johannessen, 2005, The NF1 tumor suppressor critically regulates TSC2 and mTOR, Proc. Natl. Acad. Sci. USA, 102, 8573, 10.1073/pnas.0503224102 · DOI · Paper page
- Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J. Clin. Oncol., 24, 2137, 10.1200/JCO.2005.05.2308 · DOI · Paper page
- Kim, 2010, Mouse models for breast cancer metastasis, Biochem. Biophys. Res. Commun., 394, 443, 10.1016/j.bbrc.2010.03.070 · DOI
- McGillicuddy, 2009, Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis, Cancer Cell, 16, 44, 10.1016/j.ccr.2009.05.009 · DOI · Paper page
- Miller, 2000, MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ, J. Natl. Cancer Inst., 92, 1185, 10.1093/jnci/92.14.1185a · DOI · Paper page
- Min, 2010, An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB, Nat. Med., 16, 286, 10.1038/nm.2100 · DOI · Paper page
- Mueller, 2000, Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients, Int. J. Cancer, 89, 384, 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R · DOI
- Mueller, 2010, Reverse phase protein microarrays advance to use in clinical trials, Mol. Oncol., 4, 461, 10.1016/j.molonc.2010.09.003 · DOI
- Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI · Paper page
- Sivaraman, 1997, Hyperexpression of mitogen-activated protein kinase in human breast cancer, J. Clin. Invest., 99, 1478, 10.1172/JCI119309 · DOI · Paper page
- Sjöblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427 · DOI · Paper page
- Sørlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. USA, 98, 10869, 10.1073/pnas.191367098 · DOI · Paper page
- Thomas, 2004, Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer, Clin. Cancer Res., 10, 8351, 10.1158/1078-0432.CCR-04-0130 · DOI
- von Lintig, 2000, Ras activation in human breast cancer, Breast Cancer Res. Treat., 62, 51, 10.1023/A:1006491619920 · DOI · Paper page
- Vousden, 2007, p53 in health and disease, Nat. Rev. Mol. Cell Biol., 8, 275, 10.1038/nrm2147 · DOI · Paper page
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin, K., Hornick, J. L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014) · Nature · doi:10.1038/nature13561 · Cited by 461
Self-citationMierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2343 · Cited by 90
“Currently, various RasGAPs with overlapping patterns of tissue distribution but with nonredundant functions have been identified (14, 15), and the tumorsuppressive functions of RasGAPs have been shown in several cancer types such as neuroblastoma, glioblastoma, melanoma, prostate cancer, and breast cancer (16-24).”
BackgroundResult
Metadata
- Authors
- McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., & Cichowski, K.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 24
- Issue
- 3
- Pages
- 365-378
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2085659118
- Cited by
- 135
- References
- 17
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 373 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. https://app.cochat.ai/papers/10.1016/j.ccr.2013.08.004
- The paper
- McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., & Cichowski, K. (2013). The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. Cancer Cell. https://doi.org/10.1016/j.ccr.2013.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.